Sangita Nangia Ajmani1, Deepa Aggarwal2, Pushpa Bhatia2, Manisha Sharma3, Vinita Sarabhai2, Mohini Paul2. 1. Department of Obstetrics and Gynecology, Kasturba Hospital, New Delhi, 110002 India ; D-117, Ajay Enclave, P.O Tilak Nagar, New Delhi, 110018 India. 2. Department of Obstetrics and Gynecology, Kasturba Hospital, New Delhi, 110002 India. 3. Department of Obstetrics and Gynecology, Hindu Rao Hospital, New Delhi, India.
Abstract
AIM: To determine the current prevalence of thyroid dysfunction in normal pregnant women and to study the impact of thyroid dysfunction on maternal and fetal outcome. METHODS: 400 pregnant women between 13 and 26 weeks of gestation were registered for the study. Apart from routine obstetrical investigations, TSH tests were done. Free T4 and anti-TPO antibody tests were done in patients with deranged TSH. Patients were followed up till delivery. Their obstetrical and perinatal outcomes were noted. RESULTS: The prevalence of hypothyroidism and hyperthyroidism was 12 and 1.25 %, respectively. Adverse maternal effects in overt hypothyroidism included preeclampsia (16.6 vs. 7.8 %) and placental abruption (16.6 vs. 0.8 %). Subclinical hypothyroidism was associated with preeclampsia (22.3 vs. 7.8 %) as compared to the euthyroid patients. Adverse fetal outcomes in overt hypothyroidism included spontaneous abortion (16.6 vs. 2.39 %), preterm birth (33.3 vs. 5.8 %), low birth weight (50 vs. 12.11 %), intrauterine growth retardation (25 vs. 4.9 %), and fetal death (16.6 vs. 1.7 %) as compared to the euthyroid women. Adverse fetal outcomes in subclinical hypothyroidism included spontaneous abortion (5.5 vs. 2.39 %), preterm delivery (11.2 vs. 5.8 %), low birth weight (25 vs. 12.11 %), and intrauterine growth retardation (8.4 vs. 4.9 %) as compared to the euthyroid women. CONCLUSIONS: The prevalence of thyroid disorders was high in our study with associated adverse maternal and fetal outcomes. Routine screening of thyroid dysfunction is recommended to prevent adverse fetal and maternal outcome.
AIM: To determine the current prevalence of thyroid dysfunction in normal pregnant women and to study the impact of thyroid dysfunction on maternal and fetal outcome. METHODS: 400 pregnant women between 13 and 26 weeks of gestation were registered for the study. Apart from routine obstetrical investigations, TSH tests were done. Free T4 and anti-TPO antibody tests were done in patients with deranged TSH. Patients were followed up till delivery. Their obstetrical and perinatal outcomes were noted. RESULTS: The prevalence of hypothyroidism and hyperthyroidism was 12 and 1.25 %, respectively. Adverse maternal effects in overt hypothyroidism included preeclampsia (16.6 vs. 7.8 %) and placental abruption (16.6 vs. 0.8 %). Subclinical hypothyroidism was associated with preeclampsia (22.3 vs. 7.8 %) as compared to the euthyroid patients. Adverse fetal outcomes in overt hypothyroidism included spontaneous abortion (16.6 vs. 2.39 %), preterm birth (33.3 vs. 5.8 %), low birth weight (50 vs. 12.11 %), intrauterine growth retardation (25 vs. 4.9 %), and fetal death (16.6 vs. 1.7 %) as compared to the euthyroid women. Adverse fetal outcomes in subclinical hypothyroidism included spontaneous abortion (5.5 vs. 2.39 %), preterm delivery (11.2 vs. 5.8 %), low birth weight (25 vs. 12.11 %), and intrauterine growth retardation (8.4 vs. 4.9 %) as compared to the euthyroid women. CONCLUSIONS: The prevalence of thyroid disorders was high in our study with associated adverse maternal and fetal outcomes. Routine screening of thyroid dysfunction is recommended to prevent adverse fetal and maternal outcome.
Authors: W C Allan; J E Haddow; G E Palomaki; J R Williams; M L Mitchell; R J Hermos; J D Faix; R Z Klein Journal: J Med Screen Date: 2000 Impact factor: 2.136
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Marcos Abalovich; Nobuyuki Amino; Linda A Barbour; Rhoda H Cobin; Leslie J De Groot; Daniel Glinoer; Susan J Mandel; Alex Stagnaro-Green Journal: J Clin Endocrinol Metab Date: 2007-08 Impact factor: 5.958
Authors: Helen B Chin; Melanie H Jacobson; Julia D Interrante; Ann C Mertens; Jessica B Spencer; Penelope P Howards Journal: Fertil Steril Date: 2015-10-30 Impact factor: 7.329
Authors: Kristin A Evans; David Q Rich; Barry Weinberger; Anna M Vetrano; Liza Valentin-Blasini; Pamela Ohman Strickland; Benjamin C Blount Journal: Reprod Toxicol Date: 2015-07-10 Impact factor: 3.143
Authors: Megan E Romano; Melissa N Eliot; R Thomas Zoeller; Andrew N Hoofnagle; Antonia M Calafat; Margaret R Karagas; Kimberly Yolton; Aimin Chen; Bruce P Lanphear; Joseph M Braun Journal: Int J Hyg Environ Health Date: 2018-03-23 Impact factor: 5.840
Authors: Brett T Doherty; Noelle Kosarek; Andy N Hoofnagle; Yingying Xu; R Thomas Zoeller; Kimberly Yolton; Aimin Chen; Bruce P Lanphear; Joseph M Braun; Megan E Romano Journal: Clin Endocrinol (Oxf) Date: 2020-01-19 Impact factor: 3.478